9 research outputs found
Ăvaluation objective de l'actionnabilitĂ© en vue du dĂ©veloppement d'une procĂ©dure rapide de sĂ©quençage Ă haut dĂ©bit pour des gĂšnes impliquĂ©s dans les maladies neurologiques : application pour les myopathies et les encĂ©phalopathies Ă©pileptiques prĂ©coces
Avec lâutilisation du sĂ©quençage Ă haut dĂ©bit, le concept de « gĂšnes actionnables » a Ă©mergĂ©. Il sâagit de gĂšnes impliquĂ©s dans des pathologies pour lesquelles il existe un traitement et/ou une prise en charge spĂ©cifique, qui pourra ĂȘtre initiĂ© en cas de diagnostic gĂ©nĂ©tique prĂ©cis. âAmerican College of Medical Genetics and Genomics (ACMG) a rĂ©digĂ© en ANNEE des recommandations initiales sur le principe dâactionnabilitĂ© et a publiĂ© une liste de 59 gĂšnes actionnables. Plus rĂ©cemment, Clinical Genome Resource (ClinGen) a proposĂ© une classification semi-quantitative permettant dâĂ©valuer lâactionnabilitĂ© clinique des gĂšnes au travers de quatre indicateurs. Sur cette base, nous avons souhaitĂ© Ă©valuer de maniĂšre objective lâactionnabilitĂ© clinique de gĂšnes impliquĂ©s dans deux thĂ©matiques dâintĂ©rĂȘt de notre laboratoire, les encĂ©phalopathies Ă©pileptiques nĂ©onatales et les myopathies, pour lesquelles peu de donnĂ©es obtenues de maniĂšre mĂ©thodologique existent Ă ce jour.Cette approche systĂ©matisĂ©e permettra par la suite de prendre en compte les donnĂ©es obtenues pour des choix stratĂ©giques, notamment de dĂ©veloppement de circuits spĂ©cifiques de diagnostic gĂ©nĂ©tique rapide, et de rĂ©flexion sur les Ă©volutions dâapproches thĂ©rapeutiques et de prise en charge des pathologies concernĂ©es.Nous avons scorĂ© lâactionnabilitĂ© clinique de 10 gĂšnes dâencĂ©phalopathies Ă©pileptiques nĂ©onatales, ainsi que de 300 couples « gĂšne-pathologie » de myopathies et du gĂšne DMD impliquĂ© dans la myopathie de DuchĂȘne, en utilisant la classification ClinGen. Nous avons Ă©galement comparĂ© les scores obtenus avec ceux de 36 gĂšnes actionnables appartenant Ă la liste ACMG et publiĂ©s dans une Ă©tude de Webber et al.Nous avons dĂ©montrĂ© que les 10 gĂšnes dâencĂ©phalopathies Ă©pileptiques nĂ©onatales, que nous avions sĂ©lectionnĂ©s, Ă©taient actionnables avec les mĂȘmes scores dâactionnabilitĂ© clinique que ceux des gĂšnes spĂ©cifiĂ©s initialement comme actionnables par lâACMG. Nous avons objectivĂ© que la plupart des 300 couples « gĂšne-pathologie » des myopathies de la liste FILNEMUS, nâĂ©taient pas actionnables. En prenant en compte les nouvelles approches thĂ©rapeutiques proposĂ©es en recherche pour certains gĂšnes, nous avons pu montrer que les gĂšnes de myopathies concernĂ©s devenaient alors actionnables. LâactionnabilitĂ© des dix gĂšnes dâencĂ©phalopathies Ă©pileptiques nĂ©onatales va nous permettre de dĂ©velopper un circuit de diagnostic rapide par sĂ©quençage Ă haut dĂ©bit afin de proposer un traitement adaptĂ© le plus tĂŽt possible. Les donnĂ©es obtenues concernant lâactionnabilitĂ© clinique des couples « gĂšne-pathologie » de myopathies constituent une ressource de rĂ©flexion concernant les Ă©volutions de prise en charge des pathologies concernĂ©es.En conclusion, lâactionnabilitĂ© clinique des gĂšnes nâest pas un concept figĂ©, et est amenĂ©e Ă Ă©voluer dans les prochaines annĂ©es avec lâavancĂ©e des recherches. Le dĂ©veloppement rĂ©cent dâoutils mĂ©thodologiques de dĂ©termination de lâactionnabilitĂ© clinique pourra ĂȘtre intĂ©grĂ© dans les choix stratĂ©giques dâapproches diagnostiques et de prise en charge des patients atteints de maladies gĂ©nĂ©tiques
Brevibacterium massiliense bacteremia
Brevibacterium massiliense infection in man is rare. We report here the second case with isolation of B. massiliense in human. This micro-organism requires specific laboratory investigations such as 16S rRNA gene sequencing for accurate species identification. The clinical outcome was favorable
Fatal Neisseria macacae infective endocarditis: first report
International audienceWe present here the first case of N. macacae infective endocarditis in a 65-year-old man with a native aortic valve infection complicated by a peri-aortic abscess. N. macacae was isolated from blood culture and was found on the cardiac valve using 16S rDNA detection. Despite an appropriate antibiotic therapy, and aortic homograft replacement, and mitral repair, the patient died 4 days after surgery from a massive hemorrhagic stroke
Evaluation of empirical treatment for blood culture-negative endocarditis
International audienceObjectives: Much progress has been made in understanding the main causes of blood culture-negative endocarditis (BCNE). Few studies concerning BCNE treatment (due to previous antibiotics used or fastidious pathogens) are available. We performed this study to evaluate the effectiveness of our therapeutic protocol in BCNE, based on compliance with the protocol, outcome and 1 year mortality. Patients and methods: We collected prospectively and analysed retrospectively cases of BCNE between 2002 and 2014, using a simplified and standardized protocol developed by our multidisciplinary team. We apply two kinds of protocols to treat BCNE, which include only four intravenous antimicrobial agents: amoxicillin, vancomycin, gentamicin and amphotericin B. Results: We had 177 patients with definite BCNE. There were 154 (87.0%) patients treated with both appropriate antimicrobial agents and appropriate duration of treatment. We analysed the causes of inappropriate treatment in 13 (7.3%) cases and inappropriate duration in 10 (5.6%) cases. The treatment changes were justified in all cases except one of discharge against medical advice. The fatality rate was 5.1% (nine cases) and all deaths occurred in the group of patients who were treated with appropriate treatment; however, four deaths were not attributable to empirical treatment failure. Concerning the other deaths, the lack of surgical management, in association with empirical treatment, could explain our protocol's failure, such as poorly tolerated surgery. Conclusions: Our protocol is efficient and our mortality rate was low, compared with the literature review. This may result from a strategy that uses a sampling procedure and a standardized protocol at the same time
Objective evaluation of clinical actionnability for genes involved in myopathies: 51 promising genes
International audienc
Objective evaluation of clinical actionnability for genes involved in myopathies: 51 promising genes
International audienc
Objective Evaluation of Clinical Actionability for Genes Involved in Myopathies: 63 Genes with a Medical Value for Patient Care
International audienceThe implementation of high-throughput diagnostic sequencing has led to the generation of large amounts of mutational data, making their interpretation more complex and responsible for long delays. It has been important to prioritize certain analyses, particularly those of âactionableâ genes in diagnostic situations, involving specific treatment and/or management. In our project, we carried out an objective assessment of the clinical actionability of genes involved in myopathies, for which only few data obtained methodologically exist to date. Using the ClinGen Actionability criteria, we scored the clinical actionability of all 199 genes implicated in myopathies published by FILNEMUS for the âNational French consensus on gene Lists for the diagnosis of myopathies using next generation sequencingâ. We objectified that 63 myopathy genes were actionable with the currently available data. Among the 36 myopathy genes with the highest actionability scores, only 8 had been scored to date by ClinGen. The data obtained through these methodological tools are an important resource for strategic choices in diagnostic approaches and the management of genetic myopathies. The clinical actionability of genes has to be considered as an evolving concept, in relation to progresses in disease knowledge and therapeutic approaches